Innovating and Delivering New Technologies

Cordis is proud to have completed the acquisition of MedAlliance and its novel SELUTION SLR™ Drug-Eluting Balloon (DEB). Using breakthrough proprietary technology, MedAlliance has found a unique solution to the challenge of controlled and sustained sirolimus release with the SELUTION SLR™ DEB. Cordis and MedAlliance combined are committed to accelerating the development and commercialization of innovative cardiovascular interventional products around the world.

The SELUTION SLRTM Drug-Eluting Balloon is not approved for sale in every country. Please contact your local representative for additional information

Need Help?

We’re here with the support and information to help you make the right decision for your patients.